Glioblastoma is a severe type of primary brain tumor, and its highly invasive character is considered to be a major therapeutic obstacle. Phospholipase D (PLD) isozyme is overexpressed in various human tumor tissues and involved in tumorigenesis. However, the molecular mechanisms by which PLD enhances glioma invasion are unknown. In this study, we demonstrate that the increased expression of PLD and its enzymatic activity in the glioma stimulate the secretion and expression of matrix metalloproteinase (MMP)-2 and induce the invasiveness of glioma cells. The upregulation of MMP-2 induced by phosphatidic acid (PA), the product of PLD, was mediated by protein kinase C (PKC), protein kinase A (PKA), nuclear factor-kB (NF-kB) and Sp1 and it enhanced glioma cell invasion. PA activated PKC and PKA and induced the nuclear translocation and transactivation of NF-kB. PA also increased the binding of NF-kB and Sp1 to the MMP-2 promoter. Mutation of the NF-kB-or Sp1-binding sites significantly attenuated MMP-2 promoter activity. This is the first report to show that NF-kB and Sp1 are essential transcriptional factors linking PLD to MMP-2 upregulation, providing evidence that PLD contributes to glioma progression by enhancing MMP-2 expression and tumor cell invasion via PKC/PKA/NF-kB/Sp1-mediated signaling pathways.
Introduction
Glioma, the most common primary brain tumor, is one of the most aggressive and lethal neoplasms. Glioma invasion into normal brain tissue is a major challenge to clinical intervention because these tumors highly infiltrate the surrounding brain tissue. Thus, a better understanding of the mechanisms of invasion within the brain will aid in the development of new strategies for curative treatment of glioma.
Glioma invasion into normal brain regions involves the disruption of the extracellular matrix and subsequent penetration into adjacent brain structures. This process is accomplished in part by tumor cellsecreted matrix metalloproteinases (MMPs) (1) . Elevated levels of MMPs have been reported to be correlated with tumor cell invasiveness in gliomas and are believed to play an important role in cellular invasion and metastasis (1) (2) (3) .
Although many of the biochemical mechanisms of invasion are similar for different cancers, brain tumor cells express different types of proteolytic enzymes to successfully cross brain structures. In particular, MMP-2 and MMP-9 levels increase with tumor progression in gliomas and are thus known as key enzymes in the invasion (4) . Numerous studies have demonstrated that elevated MMP-2 levels correlate with increased invasiveness in gliomas (5, 6) . MMP-2 is known to be produced as a pro-MMP-2 (72 kDa) and to be an active-MMP-2 (62 kDa) by proteolytic processing. MMP-2 activity has been reported to be the best predictor of glioma invasion (3) . Furthermore, the upregulation of MMP-2 expression by other molecules enhanced glioma invasion in several in vitro and in vivo model systems (7) . However, the regulatory mechanism of MMP-2 expression has not been well characterized as those in MMP-9 have been.
Phospholipase D (PLD) has emerged as a critical regulator of cell proliferation and survival and prevents apoptosis (8) (9) (10) . PLD catalyzes the hydrolysis of phosphatidylcholine to generate a lipid mediator, phosphatidic acid (PA) (11) . Two mammalian isozymes of phosphatidylcholine-specific PLD (PLD1 and PLD2) have been identified. Abnormalities in PLD expression and activity have been observed in many human cancers (8) . We previously reported that the overexpression of the PLD isozymes causes anchorage-independent growth and the upregulation of MMP-9 activity (12) .
PLD activity has been implicated in invasion and correlated with increased protease secretion (13) (14) (15) . These findings underscore the importance of elucidating the molecular mechanisms by which PLD regulates invasion, a critical aspect of tumor biology. However, the precise regulatory mechanisms responsible for PLD-induced MMP expression and cancer cell invasion are not well understood.
In the present study, we show that the molecular mechanism by which PLD enhances glioma invasion involve the upregulation of MMP-2. We found that the elevated expression of PLD isozymes and their enzymatic activity is important for inducing the secretion and expression of MMP-2 and glioma invasion. PA activated protein kinase C (PKC) and protein kinase A (PKA) and enhanced the binding of nuclear factor-jB (NF-jB) and Sp1 to the MMP-2 promoter, suggesting that it may ultimately increase MMP-2 expression and invasion. Here, we report that NF-jB and Sp1 are key transcription factors for the induction of MMP-2 by the PLD-signaling pathway. Collectively, these findings provide evidence that the overexpression of PLD contributes to glioma progression by enhancing MMP-2 gene transcription and tumor cell invasion.
Materials and methods

Materials
PA was purchased from Sigma (St Louis, MO). Inhibitors for MMP-2 (MMP-2 Inhibitor I), Sp1 (Mithramycin A), PKC (GÖ 6976, Rottlerin, Ro-31-8220), PKA (H89, KT5720), Src (PP2), mitogen-activated protein kinase (MAPK) family (extracellular signal-regulated kinase; PD98059, U0126, p38; SB203580, c-jun N-terminal kinase; SP600125), mTOR (Rapamycin), PI3K (wortmannin) and NF-jB [pyrrollidine dithiocarbamate (PDTC)] were purchased from Calbiochem (La Jolla, CA).
Cell culture
Human glioma cells, U87, U373, A172 and T98G (obtained from American Type Culture Collection, Manassas, VA) and human normal astrocytes (obtained from Applied Cell Biology Research Institute, Kirkland, WA) were cultured in Dulbecco's modified Eagle's medium supplemented with 10% heat-inactivated fetal bovine serum. U87 cells stably overexpressing wild-type (wt) and a catalytically inactive mutant (mt) of human PLD isozyme (K898R for PLD1 and K758R for PLD2) were obtained by transfection using Lipofect-AMINE Plus. Transfected cells were selected with G418 (700 lg/ml).
Human glioblastoma tissue analysis
Human glioblastoma specimens were obtained by surgical resection of five glioblastoma tissues. For each carcinoma sample, adjacent normal tissues were collected for comparison. All the samples were immediately frozen and stored in liquid nitrogen until use.
Immunoprecipitation and western blot analysis
The immunoprecipitation assay was performed as described previously (16) . Immunoprecipitates were captured with protein A-sepharose (Amersham Biosciences, Piscataway, NJ) and boiled in sodium dodecyl sulfate sample buffer. Immunoblot analysis was performed as described previously (16) . A polyclonal antibody that recognizes both PLD1 and PLD2 was generated as described previously (12) . Antibodies against MMP-2, b-tubulin, a-tubulin, phospho-IjB, IjB, NF-jB (p65) and Sp1 were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies against pan-phospho-PKC and phospho-PKA were obtained from Cell Signaling Biotechnology (Beverly, MA). Enhanced chemiluminescence reagents were obtained from Amersham Biosciences.
Gelatin zymography U87 cells were seeded and refreshed with serum-free Dulbecco's modified Eagle's medium. The activity of electrophoretically separated gelatinolytic enzymes in the conditioned media was analyzed as described previously (17) . Equal amounts of conditioned media were mixed with 2Â zymogram buffer and then electrophoresed on sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels containing 1 mg/ml gelatin. For measurement of MMP-9 secretion, the conditional media were concentrated using centricon. After electrophoresis, the gels were washed with 2.5% Triton X-100 and incubated with developing buffer and then stained with 2% Coomassie Blue solution. Zones of gelatinolytic activity were detected as a clear band on a dark background. Inverted images are presented.
In vitro invasion assays Invasion assays were done using Boyden chambers with a polycarbonate nucleopore membrane (Corning, Corning, NY). The cells in serum-free media were seeded onto the upper portion of a 24-well Matrigel chamber. The lower compartment contained Dulbecco's modified Eagle's medium with 10% fetal bovine serum. The cells that migrated to the lower surface of the filter were fixed and stained with crystal violet and then counted in five random fields per well, and the extent of invasion was expressed as an average number of cells per microscopic field.
RNA isolation and reverse transcription-polymerase chain reaction Total RNA was isolated by the Trizol method (Sigma). First-strand complementary DNA was synthesized using AMV-RTase (Promega, Madison, WI), and polymerase chain reactions (PCRs) were performed. The oligonucleotide primer sequences used were as follows: glyceraldehyde-3-phosphate dehydrogenase sense 5#-GTG-GTCTCCTCTGACTTCAAC-3# and antisense 5#-TCTCTTCCTCTTGTGCTC-TTG-3# and MMP-2 sense 5#-TCCTTTCACAACCTTCTGTGG-3# and antisense 5#-GGGAACCATCACTATGTGGG-3#. PCR products were analyzed by agarose gel electrophoresis with ethidium bromide staining.
Transfection
The expression vector for wt and dominant-negative PKC isoforms a, bII, c and f were a gift from Jang So Jeon (Kwangju Institute of Science and Technology, Korea). Small-interfering RNA (siRNA) specific for human PLD1 and PLD2 were synthesized from Dharmacon (Lafayette, CO). The siRNA sequence for PLD1 is 5#-AAGGUGGGACGACAAUGAGCA-3# and the siRNA sequence for PLD2 is 5#-CUCUGUCAUGGCAUGGUAG-3#. Stealth RNA interference was used as a negative control. Plasmid or siRNA was transiently transfected into U87 cells using Lipofectamine Plus reagent (Invitrogen) according to the manufacturer's instruction.
Luciferase reporter assays
The cells were seeded and transfected with 100 ng of promoter constructs and 10 ng of pRL-TK (internal control). The activities of firefly and Renilla luciferase in the cellular extracts were measured using the Dual-Luciferase Assay kit (Promega). For the MMP-2 promoter assays, pGL2 luciferase reporter vectors containing full-length human MMP-2 promoter and a series of 5# deletion constructs of MMP-2 promoters were kindly provided by Dr Benveniste (University of Alabama, Birmingham, AL) and subcloned into pGL4-basic vector to produce pGL4-MMP-2. For the NF-jB transactivation assay, pGL2-3X NF-jB, which contained three tandem repeats of the NF-jB-binding motif, was used. A site-specific mutation was introduced into the NF-jB (for NF-jB-A, À1189 TGGAGTTCCC À1180 / TGCAGTTCAA and for NFjB-B, À528 GGGACCTTCC À519 / GGCACCTTAA) and Sp1-A (À90 GGGCGG À85510 / CTAGAT)-binding sites on the MMP-2 promoter using a site-directed mutagenesis kit (Staratagene, LaJolla, CA), resulting in NF-jB or Sp1 mt constructs (mNF-jB-A, mNF-jB-B, mNF-jB-A/B and mSp1-A).
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation assay was carried out as described elsewhere (18) with minor modifications. The cells were incubated with 1% formaldehyde and lysed. One-fourth of the chromatin solution was reserved for input. The remaining solution was incubated with antibody and then incubated with protein A-sepharose. The Immunoprecipitates were reverse cross-linked. PCR was performed on the phenol-chloroform-extracted DNA with specific primers of NF-jB-and Sp1-binding sites in the MMP-2 promoter. The primers used for PCR were NF-jB-A, 5#-ACCCAGCACTCCACCTC-3# (sense) and 5#-AGGTCGAATCCCAATTTTG-3# (antisense); NF-jB-B, 5#-GGTTCCA-ACGTCTCTAACG-3# (sense) and 5#-CAGATGATCAGCCACAATG-3# (antisense) and Sp1, 5#-GGGAAAAGAGGTGGAGAAAG-3# (sense) and 5#-GTCCTGGCAATCCCTTTG-3# (antisense). The amplified PCR product was analyzed on agarose gel.
Immunocytochemistry
For immunocytochemical analysis, cells were fixed with 4% formaldehydephosphate-buffered saline, followed by permeabilization with 0.2% Nonidet P-40-phosphate-buffered saline. Cells were blocked in 5% bovine serum albumin and then incubated with primary antibody/bovine serum albumin. Cells were washed and incubated with anti-rabbit Texas red-conjugated secondary antibody (Jackson Immunoresearch Laboratories, West Grove, PA) containing 1 mg/ml Hoechst. Cells were washed and mounted with anti-fading mounting medium (Vector Laboratory, Burlingame, CA). Cells were visualized and images were collected using a fluorescence microscope.
Separation of nuclear and cytosolic fractions
Nuclear and cytosolic fractions were separated with a commercially available kit according to the manufacturer's protocol (Pierce, Rockford, IL). The purity of the nuclear and cytosolic fraction was ensured by immunoblotting with Lamin B and a-tubulin.
Statistics
The results are expressed as means ± standard errors of the number of determinations indicated. Statistical significance of differences was determined by analysis of variance.
Results
Elevated PLD expression is required for MMP-2 secretion
To investigate the role of PLD in the invasiveness of glioma cells, we first studied the involvement of PLD expression in the secretion of MMPs in various human glioma cell lines and normal human astrocytes. Western blot analysis of cell lysates using an antibody to PLD that recognizes both PLD1 and PLD2 showed significantly elevated expression of PLD1 in four glioma cells in comparison with that of normal astrocytes ( Figure 1A ). PLD1 was dominantly expressed in these cells, and PLD2 was very weakly detected after immunoprecipitation ( Figure 1B ). As measured by zymography, four glioma cells expressing high levels of PLD1 revealed significantly enhanced secretion of MMP-2 at the basal level as well as PA treatment ( Figure 1A ), suggesting a correlation between PLD expression and MMP-2 secretion. MMP-2 was the major MMP type secreted by U87 cells. Thus, to verify the specific requirement for PLD expression in MMP-2 secretion, U87 cells were transfected with siRNA specific for PLD1 and PLD2. The knockdown of PLD isozymes suppressed MMP-2 activity ( Figure 1B ). In addition, we confirmed that both PLD1 expression and MMP-2 secretion were dose dependently abolished by siRNA knockdown of PLD1 ( Figure 1B ). We sometimes observed pro-MMP-2 and active MMP-2 expression and other times only active MMP-2. We sought to investigate whether PLD1 is elevated in glioma tumors. Five human glioblastoma tissues paired with the corresponding adjacent normal tissues were analyzed for reverse transcription-PCR. The expression of PLD1 in the glioma tissues was increased in comparison with that of the adjacent normal tissues ( Figure 1C ). These data were consistent with the recent finding that PLD expression is upregulated in many cancer tissues, including breast, renal, colorectal and gastric cancers (19) . These results suggest that PLD expression correlates with MMP-2 secretion in glioma cells.
PLD activity is involved in the induction of MMP-2 secretion and the promotion of glioma cell invasion Next, to examine whether the catalytic activity of PLD is involved in MMP-2 secretion and invasion, we used U87 cells that had been stably transfected with vectors, wtPLD1, PLD2 or the catalytically inactive mtPLD1 (K898R) and PLD2 (K758R). Glioma cells expressing wtPLD isozymes, but not mtPLD isozymes, showed significantly Role of PLD in MMP-2 expression and glioma invasion increased MMP-2 secretion, suggesting that MMP-2 secretion is clearly dependent upon PLD activity ( Figure 2A) . Moreover, the effect of PLD was activity dependent because PA, the product of PLD activity, significantly enhanced MMP-2 secretion in a dose-and timedependent manner ( Figure 2B ). The involvement of PLD activity in MMP-2 secretion received further support when 1-butanol was used to block PA production by PLD, by virtue of the formation of phosphatidylbutanol through the transphosphatidylation reaction. As shown in Figure 2C , phorbol 12-myristate 13-acetate, a PKC activator that is well known to activate PLD, increased MMP-2 secretion, and 1-butanol inhibited phorbol 12-myristate 13-acetate-induced MMP-2 secretion. However, an identical concentration of 3-butanol, an inactive analog for PLD-mediated PA formation, did not have a significant effect on MMP-2 secretion. This activity dependency was further confirmed by inducing the accumulation of endogenous PA by treatment of propranolol, a PA phosphohydrolase inhibitor. Propranolol increased MMP-2 activity ( Figure 2C ). Therefore, these results suggest that PLD activity is involved in MMP-2 secretion.
We performed invasion assays of glioma cells to investigate whether PLD activity is also a critical factor in the invasiveness of glioma cells. Similar to MMP-2 secretion, wtPLD isozymes, but not mtPLD isozymes, increased the invasion of the U87 cells (P , 0.05) and PA also promoted significantly invasiveness in a dose-and timedependent manner (P , 0.02 or P , 0.002) ( Figure 2D ). These results suggest that the enzymatic activity of PLD is involved in the upregulation of MMP-2 secretion and invasion.
PLD activity is involved in the upregulation of MMP-2 expression Because MMP-2 activity was increased by PLD on zymography, we next examined whether PLD increases MMP-2 expression. The U87 cells were transfected with siRNA for control, PLD1 or PLD2 and incubated in serum-free media for 24 h. The conditioned media were subjected to gelatin zymography, and the cell lysates were subjected to immunoprecipitation and western blot using anti-PLD antibody. Right panel: siRNA for PLD1 was transfected at the indicated dose. The gelatinolytic activity of MMP2 was measured by zymography using the conditioned media, and the cell lysates were analyzed by western blotting using antibody to PLD. b-Tubulin was used as loading control. (C) PLD1 expression between glioblastoma (T) and adjacent normal tissues (N) was analyzed by reverse transcription-PCR. The levels of PLD expression were determined by densitometer analysis. Data are representative of three independent experiments.
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overexpression of wtPLD isozymes, but not mtPLD isozymes, enhanced the expression of MMP-2 messenger RNA and its promoter activity, which suggests that PLD activity is involved in the upregulation of MMP-2 expression (P , 0.05) ( Figure 3A) . Moreover, PA increased the level of messenger RNA as well as the protein level of MMP-2 in a time-or dose-dependent manner in whole-cell lysates, which is consistent with the results of zymography ( Figure 3B , upper and middle panel). PA also increased the expression of MMP-2 from the conditional media using antibody to MMP-2. Moreover, PA significantly and consistently increased MMP-2 promoter activity in a dose-dependent manner ( Figure 3B , lower panel). This activity dependency was further confirmed by treatment with propranolol, which induced MMP-2 protein expression in the cell lysates and conditional media ( Figure 3C ). We also confirmed that PA-induced MMP-2 expression occurs through increased transcription using actinomycin D, an RNA synthesis inhibitor (data not shown). Furthermore, PA also stimulated MMP-2 messenger RNA expression and its promoter activity in normal human astrocytes (P , 0.05) ( Figure 3D ). These results indicate that PLD activity is significantly involved in the expression of MMP-2 in glioma cells and astrocytes.
PA-induced MMP-2 secretion, expression and invasion of glioma cells are mediated via PKA-, PKC-, NF-jB-and Sp1-signaling pathways We examined the effects of inhibitors to investigate the molecular mechanism of signaling pathways involved in PA-induced MMP-2 secretion and expression. PA-induced MMP-2 secretion in glioma cells was significantly suppressed by pretreatment with inhibitors for PKC (GÖ 6976, rottlerin and Ro-31-8200), PKA (KT5720 and H89), PI3K (wortmannin), mTOR (rapamycin) and Src kinase (PP2), but not with inhibitors of MAPK (U0126, SB203580 and SP600125) ( Figure 4A, upper panel) . Interestingly, we found that inhibitors of transcription factors, NF-jB (PDTC) and Sp1 (mithramycin A) significantly suppressed PA-stimulated MMP-2 secretion in a dose-dependent manner ( Figure 4A, middle panel) . NF-jB is known to upregulate MMP-9. Thus, we examined the possibility of MMP-9 and NF-jB for PA-induced gelatinolytic activity. Because U87 cells are known to secrete predominantly MMP-2 and secrete very slightly MMP-9, the conditioned media were highly concentrated and analyzed by zymography. MMP-2 was highly secreted in a basal level and significantly increased by PA. MMP-9 was also increased by PA ( Figure 4A, bottom panel) . PDTC suppressed both PA-induced MMP-2 and MMP-9 secretion, suggesting that PA increase the secretion of MMP-9 as well as MMP-2 via NF-jB although MMP-2 is a predominant proteolytic enzyme in glioma. The zymography data obtained using various inhibitors were in agreement with those obtained from promoter assays (P , 0.05) ( Figure 4B ). We found that inhibitors for MAPK did not affect MMP-2 promoter activity (data not shown). Furthermore, rottlerin, H89, PDTC and mithramycin A suppressed PA-mediated invasion (P , 0.02 or P , 0.005) ( Figure  4C ). The inhibitor for MMP-2 (MMP-2 inhibitor I) blocked 
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PA-induced MMP-2 activity as well as PA-stimulated invasion (P , 0.005) ( Figure 4D, upper panel) , indicating the involvement of MMP-2 in PA-induced invasion. We examined whether the inhibitor affects MMP-2 secretion. MMP-2 inhibitor I did not affect PA-induced MMP-2 secretion in conditional media using anti-MMP-2 antibody but decreased the gelatinolytic activity of MMP-2 ( Figure 4D, lower  panel) .
Furthermore, we investigated whether the MMP-2 inhibitor suppresses the gelatinolytic activity of MMP-9. To detect MMP-9 activity, the conditioned media were highly concentrated and analyzed by zymography. MMP-2 inhibitor I at the same concentration blocked the activity of MMP-2 but not MMP-9, suggesting that the inhibitor might be selective for MMP-2 ( Figure 4D, lower panel) . However, since MMP-2 inhibitor I has not been tested against the vast majority of MMPs, it could not be excluded that the inhibitor might affect other MMPs in addition to MMP-2. Taken together, these results show that the PKC-, PKA-, NF-jB-and Sp1-mediated signaling pathways are involved in PA-induced MMP-2 activity, expression and invasion in U87 cells.
PA activates NF-jB and increases the DNA-binding activity of NF-jB and Sp1 and the transcription of MMP-2
Because it was previously demonstrated that NF-jB is recruited for the MMP-9 promoter (10), we further investigated how NF-jB is involved in PA-induced MMP-2 expression. First, we examined whether PA induces NF-jB activation in U87 cells. Immunocytochemical analysis revealed that NF-jB was rapidly translocated from Fig. 3 . PLD activity is required for MMP-2 expression at both the transcriptional and post-transcriptional levels. (A) Total RNA from U87 cells expressing empty vector, wtPLDs and mtPLDs was isolated and subjected to reverse transcription-PCR analysis. The messenger RNA levels of MMP2 were determined by densitometer analysis (upper panel). These cells were transfected with luciferase reporter plasmid containing MMP-2 promoter region (pGL4-MMP-2) for 24 h and its luciferase activity was measured (lower panel).
Ã P , 0.05 verse vector-transfected cells. (B) The U87 cells were treated with PA at the indicated concentrations for 24 h or 100 lM PA for the indicated times. Total RNA was isolated and subjected to reverse transcription-PCR (top). The cell lysates and conditioned media were analyzed by western blot using the indicated antibody (middle). The messenger RNA and protein levels of MMP2 were determined by densitometer analysis. The cells were transfected with pGL4-MMP-2 for 24 h and treated with PA at the indicated concentrations for 24 h and the luciferase activity was measured. The transfection efficiency was normalized by the cotransfection of Renilla luciferase reporter vector (pRL-TK) (bottom). Data are expressed as the mean of the means ± SDs of three independent experiments. (C) The U87 cells were treated with propranolol at the indicated concentrations for 36 h. The cell lysates and conditioned media were analyzed by western blot using the indicated antibody. (D) Human normal astrocytes were treated with 100 lM PA for 24 h and subjected to reverse transcription-PCR analysis (left panel). The astrocytes were also transfected with pGL4-MMP-2 and treated with PA (100 lM) for 24 h and their luciferase activity was measured (right panel).
Ã P , 0.05 verse control. Data are representative of three independent experiments. the cytoplasm to the nucleus after 1 h of PA stimulation ( Figure 5A , upper panel). However, NF-jB was exported from the nucleus to the cytoplasm after 24 h of PA stimulation (data not shown). We also found that NF-jB was rapidly translocated from the cytoplasm to the nucleus after 30 min of PA stimulation as analyzed by western blot ( Figure 5A, middle panel) . To analyze these results, U87 cells were transfected with a luciferase reporter gene containing a tripletandem repeat of an NF-jB-binding motif (pGL2-3X NF-jB). PA increased NF-jB transactivation (P , 0.02) ( Figure 5A , bottom panel). These results demonstrate that PA induces nuclear localization and the transactivation of NF-jB in glioma cells. We next tried to identify the NF-jB-binding sites responsible for PA-induced MMP-2 expression. We found two putative NF-jBbinding sites in the MMP-2 promoter. To determine whether NF-jB could directly bind to the MMP-2 promoter in vivo and to further define the NF-jB response elements in the promoter, we performed a chromatin immunoprecipitation assay. The MMP-2 genomic fragments captured by anti-p65 antibody were detected by PCR using specific primers designed to amplify a 231 bp containing NF-jB-A (À1189 to À1180) or a 257 bp containing NF-jB-B (À528 to À519).
These two sites are $660 bp away from each other. NF-jB binds weakly to the two sites at the basal level. The binding of NF-jB to the MMP-2 promoter was increased by treatment with PA for 1 h ( Figure 5B, middle panel) . The results suggest that NF-jB-A and NF-jB-B sites are capable of binding NF-jB and PA increases the binding of NF-jB to the MMP-2 promoter. Furthermore, mutagenesis of the NF-jB-A or NF-jB-B sites attenuated both basal and PAinduced MMP-2 promoter activity (P , 0.05) ( Figure 5C ). The combined mutation of these two sites (NF-jB-A/B) completely abolished basal and PA-induced MMP-2 promoter activity. These findings demonstrate the functional importance of binding of NF-jB to the MMP-2 promoter in PA-induced MMP-2 induction.
Since the transcription factor Sp1 is also known to be required for constitutive MMP-2 gene expression in astroglioma cells (20) , we tried to identify the putative Sp1-binding sites on the MMP-2 promoter. First, we measured the promoter activity using a series of 5# deletion mts (D9-D12). The D9 promoter containing the Sp1A-and Sp1B-binding sites was responsive to PA, whereas the D10 promoter containing only the Sp1B-binding site was not responsive to PA (P , 0.05) ( Figure 5D ). We performed a chromatin Ã P , 0.005 verse control cells; # P , 0.005 verse PA-treated cells. The cells were pretreated with MMP-2 inhibitor I for 1 h and then treated with 100 lM PA for 24 h. The conditioned media were analyzed by western blot using the anti-MMP-2 and subjected to zymography (lower panel, left). The conditioned media were concentrated and subjected to zymography (right). Data are expressed as the mean of the means ± SDs of three independent experiments.
Role of PLD in MMP-2 expression and glioma invasion immunoprecipitation assay to confirm Sp1-mediated MMP-2 promoter activation by PA. PA significantly increased the binding of Sp1 to the MMP-2 promoter ( Figure 5B, bottom panel) . Sp1 binds weakly to the MMP-2 promoter at the basal level. Moreover, mutagenesis of the Sp1-A-binding site suppressed both basal and PAinduced MMP-2 promoter activity (P , 0.05 or P , 0.005) ( Figure 5E ), suggesting that the Sp1-A-binding site is critical for basal and PA-induced MMP-2 expression. Although Sp1-A is absent in D10 promoter, basal promoter activity of D10 was somewhat higher than that of mtSp1-A D9 promoter. Thus, it is speculated that these results might be due to the construct difference and other mechanisms such as the presence of negative regulator in À139/À85 region. Furthermore, the ectopic expression of NF-jB and Sp1 significantly enhanced the activity of the MMP-2 promoter in the absence of PA ( Figure 5F ). These results demonstrate that two transcription factors, Sp1 and NFjB, are essential for both basal and PA-induced MMP-2 transcription.
PA-induced PKC and PKA activation is involved in NF-jB-mediated MMP-2 promoter activation
To analyze the involvement of PKC and PKA in the PA-induced upregulation of MMP-2, we examined whether PA activates PKC and PKA using anti-pan-phospho-PKC or anti-phospho-PKA antibody. Western blot analysis revealed that PA increased the phosphorylation of both PKC and PKA, and it was detected at 5 min after PA treatment ( Figure 6A ). In addition, the phosphorylation of IjB was detected at same time point. To further confirm this observation, U87 cells were transfected with various PKC or PKA expression plasmids with pGL4-MMP-2. Consistent with Figure 4B , PKA and wt PKC-a, -bII, -c or -f stimulated MMP-2 promoter activity (P , 0.05) ( Figure  6B and C). Given that PKA and PKC regulate the transcriptional activity of NF-jB (21, 22) , we investigated the involvement of PKC and PKA in NF-jB activation. The inhibitors of PKC and PKA blocked PA-stimulated NF-jB transactivation ( Figure 6D ). The inhibitors of various MAPK did not affect PA-induced NF-jB transactivation (supplementary Figure 1 is available at Carcinogenesis Online). In addition, we found that the ectopic expression of PKA and PKC increased NF-jB transactivation (data not shown). Furthermore, consistent with this finding, PKC-f-or PKA-induced MMP-2 promoter activation was significantly blocked by inhibitors of NF-jB and Sp1 ( Ã , ÃÃ , # P , 0.05) ( Figure 6E ). Therefore, these results suggest that PA activates PKC and PKA, which may in turn enhance MMP-2 expression via NF-jB-and Sp1-mediated pathways. 
Discussion
PLD expression and activity have been reported to be elevated in a wide variety of cancers and have also been shown to contribute to the transformation of cells in culture (12, 23) . It is important to elucidate the cellular function of PLD in order to determine how it contributes to tumor growth and invasion in vivo because experimental evidence has shown that the aberrant expression of PLD critically regulates its tumorigenicity (8, 12, 24) . Evidence implicating that PLD is a critical regulator of cell proliferation and survival demonstrates a potential role for PLD in human cancer (8) .
It is important to understand the molecular basis of MMP-2 upregulation critical for the induction of the invasive phenotype of glioma cells. In the present study, we demonstrate that PLD plays an important role in glioma invasion by regulating the expression of MMP-2, a key proteolytic enzyme in glioma invasion.
Until now, the precise regulatory mechanisms of MMP expression by PLD were unknown. In the present study, we found that the overexpression of PLD isozymes increased the secretion and expression of MMP-2, as well as the invasion of glioma cells. Glioma cells expressing elevated levels of PLD1 showed enhanced MMP-2 secretion in comparison with normal astrocytes, which express low levels of PLD1. Moreover, the siRNA knockdown of PLD isozymes suppressed the secretion of MMP-2. Our study shows that PLD1 is overexpressed in glioblastoma tissues as compared with normal brain tissues. Thus, our results demonstrate that increased MMP-2 secretion could be attributed to the increased expression of PLD. The addition of exogenous PA, the enzymatic product of PLD, and the overexpression of wtPLDs, but not mtPLDs, increased the activity and expression of MMP-2. It is important to note that the inhibition of PA formation through the addition of the primary alcohol 1-butanol blocked phorbol 12-myristate 13-acetate-induced MMP-2 secretion, whereas 3-butanol, which does not participate in transphosphatidylation, did not. Furthermore, propranolol strongly potentiated the secretion of MMP-2. These results demonstrate that both the activity of PLD and the intracellular accumulation of PA are important factors in MMP-2 secretion. Most glioma cells are known to constitutively express MMP-2, and their expression is correlated with the invasive potential of these tumors (3, 25) . The MMP-2 activity was predominantly detected in U87 cells and very highly increased by PA, whereas MMP-9 activity from the concentrated conditioned media was slightly enhanced by PA. We also found that PLD activity is important for the invasion of malignant glioma cells. MMP-2 expression in gliomas may be regulated by many factors, including angiopoietin-2, insulin-like growth factor-binding protein-2 and phosphatase and tensin homology (26, 27) . Although MMP-2 expression is known to be regulated by several transcriptional factors, including Sp-1, p53, NF-jB, PEA3, Ets-1 and Stat3, whether these factors are functionally active remains to be determined. Sp-1-binding sites are involved in the basal activity of the MMP-2 promoter (20) . The role of NF-jB in the expression of MMP-2 in glioma is unknown, even though NF-jB is constitutively activated in cancer and notably increased NF-jB target gene expression in actively invading cells in vivo, suggesting that NF-jB plays a role in invasion (28) . In the present study, we found that PA potently enhanced MMP-2 expression by inducing the nuclear translocation of NF-jB and increasing NF-jB-binding activity on the MMP-2 promoter. We identified two functional NF-jB-binding sites of the MMP-2 promoter and found that NF-jB regulated MMP-2 expression through direct interaction with the MMP-2 promoter. 
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Moreover, PA-induced MMP-2 expression and invasion were suppressed by pretreatment with NF-jB inhibitor. When the conditioned media were highly concentrated, PA also increased the proteolytic activity of MMP-9 as well as MMP-2 via NF-jB. Our study is the first to describe a molecular mechanism by which a PLD-signaling pathway promotes MMP-2 expression and the invasion of glioma cells via NF-jB.
MMP-2 is activated at the cell surface through a unique multistep pathway that involves membrane type 1 (MT1)-MMP and tissue inhibitor of metalloproteinase 2. The rapid activation of MMP-2 occurs through an MT1-MMP-dependent mechanism in glioma cells and other cells (29) (30) (31) . Furthermore, the activation of pro-MMP-2 through the NF-jB-mediated induction of MT1-MMP has recently been reported (19, 21, 32) . In this study, we found that active-MMP-2 and pro-MMP-2 were rapidly increased at an early time point by PA. This increase reached a maximum at 12 h and was maintained for 24 h. Similar to this result, we found that the nuclear translocation of NF-jB was increased at an early time point (30 min) (data not shown) and maintained for 12 h, whereas NF-jB was detected almost exclusively in the cytoplasm after 24 h. Although further studies are needed to examine the possible roles of PLD in the NF-jB-mediated induction of MT1-MMP in MMP-2 activation, PA-induced NF-jB activation seems to be involved in the activation and expression of MMP-2 in glioma cells.
Given that the Sp1 supported the constitutive expression of MMP-2 in astroglioma cells (20) , we investigated whether Sp1 is involved in PA-induced MMP-2 expression. PA promoted the transactivation of Sp1 and direct binding of Sp1 to the MMP-2 promoter. We identified one functional Sp1-binding site (between À90 and À85 bp) required for PA-mediated MMP-2 expression. Moreover, a Sp1-specific inhibitor abolished PA-induced MMP-2 activity, expression and invasion. Therefore, Sp1 also seems to mediate PA-induced MMP-2 and cell invasion.
We also found that the invasion-promoting action and MMP-2 induction by PLD-dependent signaling pathways in glioma cells are mediated by PKC and PKA. In addition, PI3K-, mTOR-and Src kinase-signaling pathways were also involved in PA-induced MMP-2 secretion. PA stimulated both PKC and PKA, which enhanced MMP-2 expression via NF-jB-and Sp1-mediated pathways. The present study elucidated the transcriptional regulation of MMP-2 by PA leading to the invasion of glioma cells and that aberrant PLD signaling activates NF-jB and Sp1 via PKC and PKA pathways and contributes to elevated MMP-2 expression and the induction of invasion. Because PLD has emerged as a critical regulator of cell proliferation, survival and invasion, understanding the functional mechanism of PLD may provide useful information for identifying potential targets for novel therapeutic strategies against malignant glioma. 
